TOP TEN perturbations for 39330_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39330_s_at
Selected probe(set): 208636_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39330_s_at (208636_at) across 6674 perturbations tested by GENEVESTIGATOR:
CML study 1 / B-CLL study 5
Relative Expression (log2-ratio):5.400674Number of Samples:75 / 441
| Experimental | CML study 1 |
| Bone marrow samples of patients with chronic myeloid leukemia (CML). | |
| Control | B-CLL study 5 |
| Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL). |
CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Relative Expression (log2-ratio):-4.980772Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (PSCA-28t28Z; post-infusion) |
| CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
| Control | CAR T cell study 4 (PSCA-28t28Z; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
B-CLL study 5 / normal bone marrow sample
Relative Expression (log2-ratio):-4.935584Number of Samples:441 / 74
| Experimental | B-CLL study 5 |
| Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |
CAR T cell study 4 (PSCA-8t28BBZ; post-infusion) / CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)
Relative Expression (log2-ratio):-4.2499247Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (PSCA-8t28BBZ; post-infusion) |
| CD8+ T cells transduced with PSCA-8t28BBZ (third generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-8t28BBZ. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
| Control | CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-8t28BBZ (third generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-4.2231073Number of Samples:3 / 3
| Experimental | oncolytic herpes simplex virus study 2 |
| Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
| Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
| Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
CAR T cell study 4 (GFP; post-infusion) / CAR T cell study 4 (GFP; pre-infusion)
Relative Expression (log2-ratio):-4.205207Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (GFP; post-infusion) |
| CD8+ T cells transduced with GFP and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing GFP (control group). Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
| Control | CAR T cell study 4 (GFP; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express GFP. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)
Relative Expression (log2-ratio):4.131749Number of Samples:3 / 4
| Experimental | expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid. | |
| Control | expO kidney cancer study 1 (granular cell carcinoma; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. |
expO kidney cancer study 1 (clear cell adenocarcinoma, NOS; metastatic) / expO kidney cancer study 1 (granular cell carcinoma; primary)
Relative Expression (log2-ratio):4.0317135Number of Samples:3 / 4
| Experimental | expO kidney cancer study 1 (clear cell adenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue obtained from a patient with primary clear cell adenocarcinoma (NOS) of the kidney. | |
| Control | expO kidney cancer study 1 (granular cell carcinoma; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. |
Langerhans cell histiocytosis study 1 / normal epidermal Langerhans cell sample
Relative Expression (log2-ratio):3.9017353Number of Samples:7 / 3
| Experimental | Langerhans cell histiocytosis study 1 |
| Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity. | |
| Control | normal epidermal Langerhans cell sample |
| Normal epidermal Langerhans cells were isolated from skin of healthy adult donors. Single cells were isolated by collagenase digestion from epidermal sheets and CD1a - expressing cells were isolated by FACS purification. Gene-chips were further analyzed for transcripts of potentially contaminating cells - no transcripts for CD3ε (T cell), CD19 (B cell) or Desmogleins 1-4 (keratinocytes) were detected, confirming purity of sorted cells. |
kidney transplantation study 14 (12 week) / normal B-cell (CD19+) sample
Relative Expression (log2-ratio):3.8781462Number of Samples:3 / 5
| Experimental | kidney transplantation study 14 (12 week) |
| CD19+ B-cell samples derived from kidney transplant patients 12 weeks post-transplantation. Samples were collected 12 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
| Control | normal B-cell (CD19+) sample |
| CD19+ B-cell samples derived from healthy control subjects. |